Importantly, the introduction of 4T1-BAG2-trp53R172H-I252R, which is equivalent to the human I254R mutation (the p53 mutation I254R is an aggregate-suppressing mutation 33), inhibited the effects of BAG2 on tumor growth and apoptosis following treatment with PTX (Figure 3H-I). The gene discussed is TP53; the disease is neoplasm.